AbbVie Submits EMA Application for Skyrizi Subcutaneous Induction in Moderate to Severe Crohn’s Disease – AbbVie
AbbVie announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) for subcutaneous (SC) induction for the treatment of adult… read more.
